{"id":"NCT00566982","sponsor":"Shionogi","briefTitle":"A Clinical Study to Evaluate the Safety of Ospemifene","officialTitle":"Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2007-12-04","resultsPosted":"2013-06-28","lastUpdate":"2018-05-18"},"enrollment":426,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atrophy","Vaginal Diseases"],"interventions":[{"type":"DRUG","name":"Ospemifene 60 mg","otherNames":["OsphenaÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ospemifene 60 mg/day","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.","primaryOutcome":{"measure":"Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear","timeFrame":"12 weeks","effectByArm":[{"arm":"Subjects on Placebo (Baseline)","deltaMin":5,"sd":27.86},{"arm":"Subjects on Ospemifene 60 mg/Day (Baseline)","deltaMin":-46,"sd":41.96}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":62},"commonTop":["Hot Flush","Nasopharyngitis","Headache","Muscle Spasms","Vulvovaginal Candidiasis"]}}